Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.01M Sell
10,621
-3,466
-25% -$514K 0.01% 1028
2026
Q1
$1.31M Buy
14,087
+134
+1% +$11.9K 0.01% 1152
2025
Q4
$1.12M Sell
13,953
-656
-4% -$54.9K 0.01% 1155
2025
Q3
$1.43M Buy
14,609
+3,726
+34% +$300K 0.01% 919
2025
Q2
$758K Buy
+10,883
New +$621K 0.01% 1129
2024
Q4
Sell
-1,917
Closed -$201K 1642
2024
Q3
$201K Buy
1,917
+162
+9% +$18.9K ﹤0.01% 1303
2024
Q2
$250K Buy
+1,755
New +$202K 0.01% 774
2024
Q1
Sell
-1,785
Closed -$231K 492
2023
Q4
$231K Hold
1,785
0.06% 246
2023
Q3
$291K Hold
1,785
0.14% 124
2023
Q2
$327K Hold
1,785
0.15% 120
2023
Q1
$238K Buy
+1,785
New +$210K 0.11% 144

Other funds holding ACLS

&Partners's ACLS Position: Q2 2026 in Review

&Partners reduced its Axcelis (ACLS) stake by 25% in Q2 2026, selling an estimated $514K and leaving 10,621 shares worth $2.01M. The position accounts for 0.01% of the portfolio, ranked #1028.

&Partners first reported a position in ACLS in Q1 2023 and has held it in 11 quarters since. 441 funds tracked by Wall St. Rank hold ACLS as of Q2 2026.

  • &Partners held 10,621 shares of Axcelis worth $2.01M as of Q2 2026.
  • &Partners sold 3,466 Axcelis shares in Q2 2026, an estimated $514K.
  • Axcelis made up 0.01% of &Partners's portfolio in Q2 2026, its #1028 holding.
  • &Partners first reported a position in Axcelis in Q1 2023 and has held it in 11 quarters since.
  • 441 funds tracked by Wall St. Rank held Axcelis as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.